UMMS Affiliation

Center for Health Policy and Research; Clinical Pharmacy Services; Commonwealth Medicine

Date

3-27-2017

Document Type

Poster

Disciplines

Health Services Administration | Health Services Research | Pharmacy and Pharmaceutical Sciences | Virus Diseases

Abstract

An evaluation of the effectiveness of HCV genotype 1 treatment with Harvoni® (ledipasvir/sofosbuvir) as measured by a sustained virological response (SVR) of 12 weeks in the MassHealth fee-for-service and Primary Care Clinician plan population. The analysis concluded that treatment was associated with a a high rate of SVR12, which means that Hepatitis C is not detected in the blood after 12 weeks.

Rights and Permissions

© 2017 University of Massachusetts Medical School

Comments

Presented at the Academy of Managed Care and Specialty Pharmacy Annual Conference 2017.

Keywords

Hepatitis C, Harvoni, ledipasvir, sofosbuvir, HCV genotype 1

 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.